Evaluation of efficacy of QR678® and QR678® Neo hair growth factor formulation in the treatment of persistent chemotherapy‐induced alopecia caused due to cytotoxic chemotherapy—A prospective pilot study. (19th October 2020)

• Record Type: Journal Article
• Authors: Kapoor, Rinky; Shome, Debraj; Doshi, Komal; Vadera, Sapna; Patel, Ghanshyam; Kumar, Vaibhav
• Is Part Of: Journal of cosmetic dermatology. Volume 19:Number 12(2020)
• Page Start: 3270
• Page End: 3279
• Publication Date: 2020-10-19
• Subjects: chemotherapy‐induced alopecia -- hair loss -- QR678 -- QR678 Neo; hair growth; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.13759
• Languages: English
• ISSNs: 1473-2130

Abstract

ABSTRACT: Background: Cancers are one of the main reasons of morbidity and mortality globally. Chemotherapy‐induced alopecia (CIA) is one of the most alarming, terrifying, and traumatic adverse effects. A range of therapeutic measures has been suggested to alleviate CIA, but at present, there is no accepted pharmacological therapy that can assure prevention or management. Aim: The aim of the present study was to evaluate the efficacy of QR 678 Neo® therapy in the treatment of persistent chemotherapy‐induced alopecia in women and men treated with cytotoxic chemotherapy for breast and lung cancers, respectively. Methods: A total of 8 male patients with history of lung cancer and 12 female patients with history of breast cancer in the age range of 25‐60 years, with WHO classification of grade I and II persistent alopecia who had undergone chemotherapy treatment, were selected for the study. At each visit, 1.5 mL solution of QR 678 ® was injected into the scalp skin of patients. A total of 8 sessions were performed at an interval of 3 weeks each. All the patients were evaluated with standard global photography, video microscopic assessment, and patient self‐assessment questionnaire at baseline, 6 months, and 1 year. Results: Marked improvement was seen in the global assessment score at 6 months (mean‐8) which was maintained even after 1 year. Mean score increase in hair count at 6 months was 12.71 which further increased at 1 year. High satisfaction score was given by patients for slowing of hair loss (mean = 4.2) and also for overall hair growth. For appearance and growth of hair, the mean value was 3.4 and 3.8, respectively. Conclusion: The formulation of QR 678 ® and QR 678 ® Neo showed to be significantly safe and efficient for chemotherapy‐induced alopecia in both men and women. Improvement in hair growth was maintained even at 1 year of follow‐up. No patient had any severe adverse effects, and injections were also easily bearable by most of them.